Περίληψη:
Coronavirus disease 2019 (COVID-19) is associated with a high rate of
thrombosis. Prolonged activated partial thromboplastin times (aPTT) and
antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The
majority of publications have not reported whether patients develop
clinically relevant persistent aPL, and the clinical significance of new
aPL-positivity in COVID-19 is currently unknown. However, the reports of
aPL-positivity in COVID-19 raised the question whether common mechanisms
exist in the pathogenesis of COVID-19 and antiphospholipid syndrome
(APS). In both conditions, thrombotic microangiopathy resulting in
microvascular injury and thrombosis is hypothesized to occur through
multiple pathways, including endothelial damage, complement activation,
and release of neutrophil extracellular traps (NETosis). APS-ACTION, an
international APS research network, created a COVID-19 working group
that reviewed common mechanisms, positive aPL tests in COVID-19
patients, and implications of COVID-19 infection for patients with known
aPL positivity or APS, with the goals of proposing guidance for clinical
management and monitoring of aPL-positive COVID-19 patients. This
guidance also serves as a call and focus for clinical and basic
scientific research.
Συγγραφείς:
Wang, Xin
Gkrouzman, Elena
Andrade, Danieli Castro Oliveira and
Andreoli, Laura
Barbhaiya, Medha
Belmont, H. Michael
Branch,
David Ware
de Jesus, Guilherme R.
Efthymiou, Maria and
Rios-Garces, Roberto
Gerosa, Maria
El Hasbani, Georges and
Knight, Jason
Meroni, Pier Luigi
Pazzola, Giulia
Petri,
Michelle
Rand, Jacob
Salmon, Jane
Tektonidou, Maria and
Tincani, Angela
Uthman, Imad W.
Zuily, Stephane
Zuo, Yu and
Lockshin, Michael
Cohen, Hannah
Erkan, Doruk
APS ACTION
